AAO News Archive
- Deal struck to develop integrin antagonist treatment
- New low-add multifocal IOLs yield higher patient satisfaction
- Regeneron, Bayer to develop AMD combination therapy
- FDA approves wide-field imaging system for newborns
- Brain mapping may someday lead to vision-restoring therapies
- FDA warns of loose safety seals on eye drops
- Stem cells regrow human lens, corneal tissue
- Details
This retrospective study shows that illuminated microcatheter-assisted trabeculotomy can treat childhood glaucoma with a better success rate and greater IOP control compared to traditional trabeculotomy.
Read more: Illuminated microcatheter-assisted trabeculotomy effective for congenital glaucoma
- Details
The early advantage aflibercept showed in treating patients with DME narrowed after 2 years of treatment, according to follow-up data from the DRCR.net Protocol T study.
Read more: Ranibizumab catches up with aflibercept at 2 years
- Details
Patients participating in OpenNotes demonstrated better recall of their medical plans, felt more in control of their care and were more likely to take their medications.
Read more: Sharing notes with patients may enhance health outcomes
- Details
An aldehyde-binding eye drop showed it can significantly reduce ocular itching and tearing.
Read more: Novel eye drop for allergic conjunctivitis shows promise
- Details
Medidur, an injectable insert that provides sustained release of flucinolone acetonide for 3 years, helps prevent recurrence of posterior uveitis.
Read more: Sustained-release corticosteroid for uveitis shows promise
- Details
This non-randomized clinical trial assessed the efficacy of 2% ibopamine, a topical drug that temporarily increases aqueous production, for diagnosing glaucoma.
Read more: Ibopamine challenge test can diagnose glaucoma stages